IMTX Quote, Financials, Valuation and Earnings

ATAI Life Sciences NV has a net margin of -16.95% compared to Immatics NV's net margin of -65715%. Immatics NV's return on equity of -16.88% beat ATAI Life Sciences NV's return on equity of -61.19%.

Immatics NV has a consensus price target of --, signalling upside risk potential of 135.92%. On the other hand ATAI Life Sciences NV has an analysts' consensus of -- which suggests that it could grow by 550.41%. Given that ATAI Life Sciences NV has higher upside potential than Immatics NV, analysts believe ATAI Life Sciences NV is more attractive than Immatics NV.

Immatics NV has a beta of 0.743, which suggesting that the stock is 25.688% less volatile than S&P 500. In comparison ATAI Life Sciences NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ATAI Life Sciences NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. ATAI Life Sciences NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $55.6M, which are larger than ATAI Life Sciences NV quarterly revenues of $40K. Immatics NV's net income of -$9.4M is higher than ATAI Life Sciences NV's net income of -$26.3M. Notably, Immatics NV's price-to-earnings ratio is -- while ATAI Life Sciences NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 5.70x versus -- for ATAI Life Sciences NV. Usually stocks with elevated PS ratios are considered overvalued.

BioNTech SE has a net margin of -16.95% compared to Immatics NV's net margin of 15.91%. Immatics NV's return on equity of -16.88% beat BioNTech SE's return on equity of -2.35%.

Immatics NV has a consensus price target of --, signalling upside risk potential of 135.92%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 20.51%. Given that Immatics NV has higher upside potential than BioNTech SE, analysts believe Immatics NV is more attractive than BioNTech SE.

Immatics NV has a beta of 0.743, which suggesting that the stock is 25.688% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $55.6M, which are smaller than BioNTech SE quarterly revenues of $1.4B. Immatics NV's net income of -$9.4M is lower than BioNTech SE's net income of $217.9M. Notably, Immatics NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 5.70x versus 8.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -16.95% compared to Immatics NV's net margin of 68.44%. Immatics NV's return on equity of -16.88% beat CureVac NV's return on equity of 21.3%.

Immatics NV has a consensus price target of --, signalling upside risk potential of 135.92%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 144.29%. Given that CureVac NV has higher upside potential than Immatics NV, analysts believe CureVac NV is more attractive than Immatics NV.

Immatics NV has a beta of 0.743, which suggesting that the stock is 25.688% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $55.6M, which are smaller than CureVac NV quarterly revenues of $543.2M. Immatics NV's net income of -$9.4M is lower than CureVac NV's net income of $371.8M. Notably, Immatics NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 5.70x versus 1.13x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -16.95% compared to Immatics NV's net margin of -14092.9%. Immatics NV's return on equity of -16.88% beat InflaRx NV's return on equity of -61.55%.

Immatics NV has a consensus price target of --, signalling upside risk potential of 135.92%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 220.48%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.

Immatics NV has a beta of 0.743, which suggesting that the stock is 25.688% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $55.6M, which are larger than InflaRx NV quarterly revenues of $136.2K. Immatics NV's net income of -$9.4M is higher than InflaRx NV's net income of -$19.2M. Notably, Immatics NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 5.70x versus 800.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.